Schonfeld Strategic Advisors LLC Takes Position in IVERIC bio Inc (NASDAQ:ISEE)
Schonfeld Strategic Advisors LLC acquired a new stake in IVERIC bio Inc (NASDAQ:ISEE) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 111,900 shares of the company’s stock, valued at approximately $960,000.
Several other hedge funds also recently added to or reduced their stakes in the company. Credit Suisse AG bought a new stake in shares of IVERIC bio in the 4th quarter valued at approximately $794,000. California Public Employees Retirement System grew its stake in shares of IVERIC bio by 34.9% in the 4th quarter. California Public Employees Retirement System now owns 58,800 shares of the company’s stock valued at $505,000 after purchasing an additional 15,200 shares during the period. Laurion Capital Management LP bought a new stake in shares of IVERIC bio in the 4th quarter valued at approximately $242,000. Tower Research Capital LLC TRC grew its position in IVERIC bio by 11,914.4% during the 4th quarter. Tower Research Capital LLC TRC now owns 18,382 shares of the company’s stock worth $158,000 after acquiring an additional 18,229 shares during the last quarter. Finally, Alpine Global Management LLC bought a new stake in IVERIC bio during the 4th quarter worth approximately $151,000. Institutional investors own 63.55% of the company’s stock.
In related news, Chairman David R. Guyer sold 3,367 shares of the stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $8.07, for a total transaction of $27,171.69. Following the sale, the chairman now directly owns 57,339 shares in the company, valued at approximately $462,725.73. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 4.30% of the stock is owned by corporate insiders.
IVERIC bio (NASDAQ:ISEE) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.39) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.11). On average, equities analysts forecast that IVERIC bio Inc will post -1.45 earnings per share for the current fiscal year.
A number of equities research analysts recently commented on ISEE shares. Wedbush started coverage on IVERIC bio in a research report on Monday, January 6th. They set an “outperform” rating on the stock. ValuEngine lowered IVERIC bio from a “sell” rating to a “strong sell” rating in a research report on Tuesday, February 4th. BidaskClub lowered IVERIC bio from a “buy” rating to a “hold” rating in a research report on Saturday, February 15th. Finally, Cowen started coverage on IVERIC bio in a research report on Friday, January 24th. They set an “outperform” rating on the stock. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. IVERIC bio currently has an average rating of “Hold” and an average price target of $1.50.
IVERIC bio Profile
IVERIC bio, Inc, a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA), a late-stage form of dry age-related macular degeneration (AMD) characterized by retinal cell death and degeneration of tissue in the central portion of the retina known as the macula; and autosomal recessive Stargardt disease (STGD1), which is an orphan inherited retinal disease (IRD).
Want to see what other hedge funds are holding ISEE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IVERIC bio Inc (NASDAQ:ISEE).
Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.